Evidence map›Paper›PMID 42488833›Full record

ArticleChinese herbal medicines2026

Huashi Baidu formula may attenuate adriamycin-induced myocardial injury via modulating NRF2-ATF3-SRXN1 axis-mediated ferroptosis.

Weijie Li, Xiang Li, Congying Huang, Yudong Liu, Zhaochen Ma, Zhaoyin Zhou, Qiuyan Guo, Congmin Xia, Chao Wang, Yute Zhong and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese herbal medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Weijie LiState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Xiang LiState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Congying HuangState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yudong LiuState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Zhaochen MaState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Zhaoyin ZhouSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Qiuyan GuoState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Congmin XiaGuang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Chao WangState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yute ZhongState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Ping WangState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Haiyu XuState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Myocardial injury is a fatal adverse effect of adriamycin (ADR), which greatly limits its clinical application. Numerous studies have shown that Huashi Baidu formula (HBF) may exert a satisfactory effect on myocardial function repair. This study aims to reveal the underlying mechanisms and main bioactive compounds (BACs) of HBF against myocardial injury. Methods: Firstly, this study established an ADR-induced mouse model to assess the protective effects of HBF against myocardial injury. Subsequently, transcriptomic profiling was conducted to screen the differentially expressed genes among the HBF treatment, ADR-induced model, and normal control groups. Following the construction and analysis of protein-protein interactions, gene set enrichment analysis, and co-expression matrix, the key targets of HBF against myocardial injury were screened and further validated based on the ADR-induced mouse model. An integrative approach combining network mapping, molecular docking, and molecular dynamics simulation was performed to identify the representative BACs. Results: Based on an ADR-induced myocardial injury mouse model, HBF significantly ameliorated myocardial injury by improving body weight loss, decreasing mortality, and rescuing severe cardiac fibrosis. A total of 361 ADR-related genes and 42 HBF therapeutic effect-related genes were identified with the thresholds Conclusion: HBF may attenuate ADR-induced myocardial injury via modulating NRF2-ATF3-SRXN1 axis-mediated ferroptosis, and emodin, rhein, and lactiflorin are potential representative BACs.

Indexed as

adriamycinferroptosisGPX4Huashi Baidu formulamyocardial injuryNRF2-ATF3-SRXN1axissystemXc

Identifiers

PMID42488833
PMCPMC13389989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.